Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α

• Verfasst von: Schmidt, Manuel [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Verfasst von: Nitsche, Andreas [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Neubauer, Andreas [VerfasserIn]
• Titel: Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α
• Verf.angabe: Manuel Schmidt, Andreas Hochhaus, Andreas Nitsche, Rüdiger Hehlmann, and Andreas Neubauer
• E-Jahr: 2001
• Jahr: June 1, 2001
• Umfang: 3 S.
• Fussnoten: Gesehen am 18.05.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2001
• Band/Heft Quelle: 97(2001), 11, Seite 3648-3650
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood.V97.11.3648
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1802477896

Abstract

Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P = .007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-α (IFN-α) therapy in “good” (n = 27) versus “poor” (n = 15) cytogenetic responders, high ICSBP levels were only observed in “good” responders (P = .0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-α, indicating an important role of ICSBP in CML.